Table 1.

List of treatment compounds, functions, doses, routes, and dosing time(s). intraperitoneal (ip), intramuscular (im), subcutaneous (sc). tBHQ, tertbutylhydoquinone; VPA, valproic acid; SS-31, Szeto-Schiller-31; ETA, endothelin receptor A; GABA, gamma-aminobutyric acid; ACE, angiotensin converting enzyme; AMPK; AMP-activated protein kinase; TRPA1, Transient receptor potential cation channel, member A1

Therapeutic	Mode of Action	Doses (mg/kg)	Route of Administration	Dosing Schedule (Post-Exposure)	N/Dose
AEOL 10150	Antioxidant	0, 10, 15, 20	sc	15 min, 6, 12, & 18 hr	32
Ambrisentan	ETA receptor blocker	0, 10, 30, 100	gavage	15 min	40
Bio300	Radioprotectant/antioxidant	0, 100, 200, 400	im	15 min	40
Captopril	ACE inhibitor	0, 30, 60, 120	ip	15 min, 3, 6, 9 hr	40
CP-80633	PDE4 inhibitor	0, 0.5, 1, 2	gavage	15 min, 3, 6, 9 hr	40
Cyproheptadine	Antihistamine, anticholinergic, antiseratonergic	0, 2.5, 5, 10	ip	15 min	30
HC-030031	TRPA1 inhibitor	0, 7.5, 15, 30	ip	15 min, 4 hr	40
Memantine	NMDA receptor antagonist	0, 5, 10, 20	gavage	15 min	30
Metformin	AMPK activator	0, 10, 35, 100	gavage	15 min, 6 hr	20
RR*	Pan TRP channel & Ca2+ inhibitor	0, 3, 6, 9	ip	15 min	30
SS31	Mitochondrial Antioxidant	0, 0.1, 0.3, 1.0	ip	15 min	40
Scopolamine	muscarinic receptor antagonist	.008, .02, .05	ip	15 min	40
Sildenafil	PDE5 inhibitor	0, 12.5, 25, 50	gavage	15 min	40
SKF 96365	SOCE & TRP Channel inhibitor	0, 10	ip	15 min	30
Valproic Acid	GABA transaminase inhibitor	0, 15, 30, 60	ip	15 min	40
Vigabatrin	GABA transaminase inhibitor	0, 37.5, 75, 150	ip	15 min	30
Zileuton	5-lipoxygenase inhibitor	0, 15, 30, 60	ip	15 min, 3, 6, 9 hr	40

^*RR mentioned here and elsewhere in the text stands for a drug name that cannot be disclosed due to a potential patent restriction.